BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37597757)

  • 1. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines.
    Bae SH; Chun SJ; Chung JH; Kim E; Kang JK; Jang WI; Moon JE; Roquette I; Mirabel X; Kimura T; Ueno M; Su TS; Tree AC; Guckenberger M; Lo SS; Scorsetti M; Slotman BJ; Kotecha R; Sahgal A; Louie AV; Kim MS
    Int J Radiat Oncol Biol Phys; 2024 Feb; 118(2):337-351. PubMed ID: 37597757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
    Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
    Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.
    Rim CH; Kim HJ; Seong J
    Radiother Oncol; 2019 Feb; 131():135-144. PubMed ID: 30773180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of local control, survival and toxicity outcomes.
    Shanker MD; Moodaley P; Soon W; Liu HY; Lee YY; Pryor DI
    J Med Imaging Radiat Oncol; 2021 Dec; 65(7):956-968. PubMed ID: 34396706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma.
    Jang WI; Kim MS; Bae SH; Cho CK; Yoo HJ; Seo YS; Kang JK; Kim SY; Lee DH; Han CJ; Kim J; Park SC; Kim SB; Cho EH; Kim YH
    Radiat Oncol; 2013 Oct; 8():250. PubMed ID: 24160944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).
    Scorsetti M; Comito T; Cozzi L; Clerici E; Tozzi A; Franzese C; Navarria P; Fogliata A; Tomatis S; D'Agostino G; Iftode C; Mancosu P; Ceriani R; Torzilli G
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1301-9. PubMed ID: 25644863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion.
    Mathew AS; Atenafu EG; Owen D; Maurino C; Brade A; Brierley J; Dinniwell R; Kim J; Cho C; Ringash J; Wong R; Cuneo K; Feng M; Lawrence TS; Dawson LA
    Eur J Cancer; 2020 Jul; 134():41-51. PubMed ID: 32460180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity.
    Loi M; Comito T; Franzese C; Dominici L; Lo Faro L; Clerici E; Franceschini D; Mancosu P; Reggiori G; Gallo P; Badalamenti M; Scorsetti M
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):927-936. PubMed ID: 32945972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiotherapy for Ultra-Central lung Tumors: A systematic review and Meta-Analysis and International Stereotactic Radiosurgery Society practice guidelines.
    Yan M; Louie AV; Kotecha R; Ashfaq Ahmed M; Zhang Z; Guckenberger M; Kim MS; Lo SS; Scorsetti M; Tree AC; Sahgal A; Slotman BJ
    Lung Cancer; 2023 Aug; 182():107281. PubMed ID: 37393758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma - Initial Experience From an Australian Liver Cancer Service.
    Liu HY; Lee Y; McLean K; Leggett D; Hodgkinson P; Fawcett J; Mott R; Stuart K; Pryor D
    Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):e194-e202. PubMed ID: 32345457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic body radiotherapy in the management of hepatocellular carcinoma: An Australian multi-institutional patterns of practice review.
    Liu HY; Lee YD; Sridharan S; Choong ES; Le H; Wang W; Khor R; Chu J; Oar A; Mott R; Smart J; Jenkins T; Anderson N; Cross S; Loo KF; Wigg A; Stuart K; Pryor D
    J Med Imaging Radiat Oncol; 2021 Jun; 65(3):365-373. PubMed ID: 33890425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Body Radiation Therapy With or Without Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone in Early-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Dumago MP; Agas RAF; Jainar CJE; Yap ET; Co LBA; Ortin TTS
    J Gastrointest Cancer; 2023 Dec; 54(4):1058-1070. PubMed ID: 37306936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic Body Radiotherapy for Lung Oligo-metastases: Systematic Review and International Stereotactic Radiosurgery Society Practice Guidelines.
    Mayinger M; Kotecha R; Sahgal A; Kim MS; Lo SS; Louie AV; Scorsetti M; Slotman B; Guckenberger M
    Lung Cancer; 2023 Aug; 182():107284. PubMed ID: 37390723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).
    Murray LJ; Sykes J; Brierley J; Kim JJ; Wong RKS; Ringash J; Craig T; Velec M; Lindsay P; Knox JJ; Dawson LA
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):900-909. PubMed ID: 29976502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thermal Ablation Versus Stereotactic Body Radiotherapy After Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.
    Nabavizadeh N; Jahangiri Y; Rahmani R; Tomozawa Y; Geeratikun Y; Chen Y; Hung A; Degnin C; Farsad K
    AJR Am J Roentgenol; 2021 Sep; 217(3):691-698. PubMed ID: 32997517
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical outcomes of stereotactic body radiation therapy for small hepatocellular carcinoma.
    Park S; Jung J; Cho B; Kim SY; Yun SC; Lim YS; Lee HC; Park J; Park JH; Kim JH; Yoon SM
    J Gastroenterol Hepatol; 2020 Nov; 35(11):1953-1959. PubMed ID: 32052884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of outcomes following surgical resection, percutaneous ablation or stereotactic body radiation therapy in early-stage, solitary and small (≤3 cm) treatment-naïve hepatocellular carcinoma.
    Maher AM; Shanker M; Liu HYH; Lee Y; Leggett D; Hodgkinson P; Pryor D; Stuart KA
    Cancer Med; 2024 Feb; 13(3):e6978. PubMed ID: 38400681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy versus radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis.
    Wang L; Ke Q; Huang Q; Shao L; Chen J; Wu J
    Int J Hyperthermia; 2020; 37(1):1313-1321. PubMed ID: 33243024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
    BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B-C hepatocellular carcinoma.
    Chiang CL; Chan MKH; Yeung CSY; Ho CHM; Lee FAS; Lee VWY; Wong FCS; Blanck O
    Strahlenther Onkol; 2019 Mar; 195(3):254-264. PubMed ID: 30413833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.